Internationale Partnersuche

Innovation & Technologie Angebot

A French Technology Transfer Office offers a new compound for the treatment of diabetes

Country of Origin: France
Reference Number: TOFR20180410001
Publication Date: 12 April 2018

Summary

A French Technology Transfer Office (TTO) offers a new compound for the treatment of glucose intolerance and more precisely for the treatment of the diabetes thanks to the administration of a known molecule at a lower dosage. This new technology targets the market of drugs dealing with metabolic disorders. 
The French TTO is looking for interested pharmaceutical corporations or biotechnology SMEs for a licensing agreement or for a technical cooperation agreement.

Description

A French Technology Transfer Office  (TTO) acting on behalf major life science research labs in Paris Region, has developed a new compound for glucose intolerance.

Conditions related to glucose intolerance are all characterized by impaired insulin and glucose metabolism. These kinds of intolerance cause serious damage such as liver fibrosis and abnormal fat liver content.



Diabetes represents high levels of blood sugar  over a long period. Therapies available for advanced stages of diabetes mainly consist in insulin injection which presents important adverse effects such as weight gain or insulin resistance.

Accordingly, there is still a need for safer and more effective treatments for metabolic disorders. 



Researchers from the French university have observed that p-cresol, known as a toxic molecule at high concentration, is able to enhance insulin secretion cells proliferation in mice at 0.5mg/kg without toxic effect. 

Indeed, the administration of non-toxic doses of this compound in preclinical models of diabetes is associated with reduced body weight and adiposity, improved glucose tolerance and enhanced glucose-stimulated insulin secretion in vivo. 



The partner sought could be a company interested in:

- a technical cooperation agreement to analyse the preclinical results of this new compound and launch clinical trials,

- a license agreement in order to commercialize the technology.

The TTO is ready to negotiate directly the patent rights transactions for specific applications.

Advantages and Innovations

Compared to existing treatments such as insulin injection which induces adverse effects, the proposed new compound shows the following advantages:

- reduction of adiposity and body weight (10 to 15% less weight)

- reduction of glucose in blood (15 to 20%)

- reduction of liver fibrosis

- improvement of glucose tolerance

- increase of glucose-stimulated insulin secretion

- increase of pancreatic islet density 

- no toxicity at therapeutic doses in vivo



This new treatment is significant because no adverse clinical signs were observed.

Stage Of Development

Under development/lab tested

Stage Of Development Comment

The proof of concept has been validated in vivo in relevant mice models.

An industrial Good Manufacturing Practice  (GMP) production is already available.

Requested partner

The partner sought could be a large corporate, medium-sized company or start-up operating in pharmaceutical, drug design or biotechnology development.

More precisely, the TTO targets companies involved in the field of metabolic disorders interested in developing some more efficient therapeutic solutions for diabetes and obesity.



A licensing agreement is open to pharmaceutical or biotech companies in case of further needed development to meet industrial and clinical challenges to commercialize drugs.



A technical cooperation agreement is open to manufacturing drugs firms which are able to drive pre-clinical and clinical testing of the new compound.